Catalent Cell and Gene Content

  1. Leveraging Platform Processes For Developing And Accelerating Novel Gene And Cancer Therapeutics 12/5/2024

    Explore how platform processes advance gene therapies, the impact of strong partnerships on patient access, and the future shaped by these collaborations.

  2. 07.14.23 -- Accelerate Development Timelines With Improved Characterization Methods 7/14/2023

    07/14/23 Outsourced Pharma Newsletter

  3. UpTempo℠ AAV Platform Process

    Catalent’s UpTempo℠ AAV platform process is a scalable, cGMP-ready process for viral vector manufacturing that can reduce the current 18-20-month development timeline for drug product in half.

  4. Exploring An Integrated Solution For AAV Vector Clinical Production

    Every choice is critical in AAV vector production. Experts share how to make the right choices, from the process and cell line, to off-the-shelf plasmids and qualified analytical methods.

  5. Accelerating Your Gene Therapy: Not All Platforms Are Created Equal

    Standardized methods, materials, and analytics are critical for overcoming hurdles in the gene therapy space. Explore how a platform approach to fast-track AAVs can enhance quality and efficiency.